Dr Reddy’s Laboratories has expanded its generic semaglutide portfolio with Obeda Pro and Obeda Plus after supplies of its original Obeda i...

Dr Reddy's Laboratories has received approval for Zytorvi, an immunotherapy targeting advanced esophageal squamous cell carcinoma. This new...

Mochi Health has reduced their prices for their GLP-1 weight loss medications. While the membership fees is entirely separate, they have me...

India's pharmaceutical companies are expected to have a mixed performance in the upcoming September quarter. Companies like Sun Pharmaceuti...

Eli Lilly has experienced significant growth, reaching a market capitalization over $1 trillion. The company aims to maintain its leadershi...

India’s obesity drug market is set for a new phase as Novo Nordisk’s oral Wegovy and Eli Lilly’s oral GLP-1 orforglipron are expected to la...

While startups such as General Catalyst-backed Voy and Mumbai-based Metago are seeing higher demand from women, Elevate Now, backed by Tita...

Facing increased scrutiny, Novo Nordisk must clarify its future strategy outside of its leading weight-loss drug. Investors are advocating ...

JM Financial retained Buy ratings on Dr Reddy’s Laboratories and Aurobindo Pharma, seeing up to 28% upside over the next 12 months. The bro...

Sandoz plans to more than double annual net sales by 2035, with biosimilars leading growth. The company will expand its biosimilar portfoli...

PGIM India Healthcare Fund generated a 22% return over the past year by over-allocating to high-growth segments like CDMO, specialty pharma...

Elara has initiated coverage on four pharmaceutical stocks, assigning Buy, Accumulate and Reduce ratings. Alkem Laboratories emerged as its...

Cipla is focusing on its tirzepatide brand Yurpeak in India's obesity market. Yurpeak has become the second largest GLP-1 product since its...

South Africa's regulator approved Sun Pharma's generic semaglutide injection for diabetes. This approval allows marketing to supplement die...

India's anti-obesity drug market sees a slowdown after initial generic semaglutide sales. Demand has eased from its peak, with growth moder...

Dr Reddy's Laboratories has achieved a significant milestone. Health Canada has approved its generic semaglutide injection. This makes Dr R...

Dr Reddy's Laboratories has secured market authorization from Health Canada for its generic semaglutide injection. This marks a significant...